Editas Medicine Inc. (EDIT)
1.28
0.01 (0.79%)
At close: Apr 17, 2025, 3:59 PM
1.28
-0.57%
After-hours: Apr 17, 2025, 07:55 PM EDT
0.79% (1D)
| Bid | 1.21 |
| Market Cap | 107.57M |
| Revenue (ttm) | 32.31M |
| Net Income (ttm) | -237.09M |
| EPS (ttm) | -2.88 |
| PE Ratio (ttm) | -0.45 |
| Forward PE | -1.22 |
| Analyst | Hold |
| Ask | 1.39 |
| Volume | 628,022 |
| Avg. Volume (20D) | 3,810,378 |
| Open | 1.26 |
| Previous Close | 1.27 |
| Day's Range | 1.25 - 1.31 |
| 52-Week Range | 0.91 - 6.69 |
| Beta | 2.16 |
About EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, whic...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 3, 2016
Employees 246
Stock Exchange NASDAQ
Ticker Symbol EDIT
Website https://www.editasmedicine.com
Analyst Forecast
According to 14 analyst ratings, the average rating for EDIT stock is "Hold." The 12-month stock price forecast is $7.5, which is an increase of 483.66% from the latest price.
Stock Forecasts4 months ago
-23.81%
Editas Medicine shares are trading lower after Sti...
Unlock content with
Pro Subscription
4 months ago
-5.03%
Editas Medicine shares are trading higher after the company announced plans to transition to an in vivo focus and initiated a reduction in headcount, aiming to eliminate approximately 65% of its workforce over the next six months.
